The basic role of the Rh factor in the pathogenesis of erythroblastosis fetalis is now well established. Concerning the prevention and treatment of this condition, however, such unanimity of opinion is lacking. All authorities agree that, for an infant born alive with manifestations of erythroblastosis, the treatment is prompt transfusion with compatible Rh negative blood. If irreversible changes are not already present, this is life saving, and such reduction in mortality as has to the present been effected is attributable largely to this therapy.
With the hope of further reducing the high toll still exacted by this disease, premature termination of pregnancy has been advocated in order to limit the period of intrauterine hemolysis. The principal division of opinion that exists in relation to the therapy of
Harville CH. CORD TRANSFUSION IN THE MANAGEMENT OF A PREMATURELY DELIVERED INFANT WITH ERYTHROBLASTOSIS FETALIS. JAMA. 1945;129(12):801–802. doi:10.1001/jama.1945.92860460001007
Customize your JAMA Network experience by selecting one or more topics from the list below.